Point72 Asia Singapore Pte. Ltd. Has $275,000 Holdings in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX)

Point72 Asia Singapore Pte. Ltd. lessened its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 12.8% in the 4th quarter, HoldingsChannel.com reports. The firm owned 72,863 shares of the company’s stock after selling 10,700 shares during the period. Point72 Asia Singapore Pte. Ltd.’s holdings in Amylyx Pharmaceuticals were worth $275,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC grew its holdings in shares of Amylyx Pharmaceuticals by 91.1% in the 3rd quarter. Barclays PLC now owns 84,572 shares of the company’s stock valued at $274,000 after buying an additional 40,319 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Amylyx Pharmaceuticals by 144.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company’s stock valued at $455,000 after purchasing an additional 83,048 shares during the period. Blue Trust Inc. raised its holdings in shares of Amylyx Pharmaceuticals by 232.1% in the 4th quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after purchasing an additional 4,883 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Amylyx Pharmaceuticals in the 4th quarter valued at about $56,000. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in Amylyx Pharmaceuticals by 43.4% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,263,353 shares of the company’s stock valued at $4,775,000 after acquiring an additional 382,608 shares during the period. Institutional investors own 95.84% of the company’s stock.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 12,425 shares of the company’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $43,114.75. Following the completion of the transaction, the insider now directly owns 194,375 shares in the company, valued at $674,481.25. This represents a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Bernhardt G. Zeiher bought 10,000 shares of the company’s stock in a transaction that occurred on Thursday, March 20th. The shares were bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the transaction, the director now owns 10,000 shares of the company’s stock, valued at $37,000. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 48,980 shares of company stock worth $168,627. 11.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Mizuho raised their target price on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an “outperform” rating in a report on Wednesday. Leerink Partnrs raised shares of Amylyx Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 6th. HC Wainwright lifted their price target on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Finally, Leerink Partners upgraded shares of Amylyx Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $4.00 to $10.00 in a report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Amylyx Pharmaceuticals presently has an average rating of “Buy” and an average price target of $9.83.

Amylyx Pharmaceuticals Stock Performance

Amylyx Pharmaceuticals stock opened at $4.52 on Friday. The firm’s fifty day moving average price is $4.12 and its 200-day moving average price is $4.21. The stock has a market cap of $402.92 million, a P/E ratio of -1.18 and a beta of -0.60. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $1.58 and a fifty-two week high of $7.27.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.03. On average, analysts predict that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.